Stereotactic radiotherapy in the treatment of lung cancer - current prospective

Abstract

Stereotactic body radiotherapy (SBRT) is the standard treatment for early-stage inoperable non-small cell lung cancer. SBRT achieves a high local control rate (74-100%), preserved quality of life, and low treatment toxicity. Different fractionation regimens are used, depending on the localization and size of the tumor, the proximity of the organs at risk, and the general condition of the patient. The radiobiology behind SBRT is largely unknown, so the precise tumor dose and the number of fractions are still a matter of discussion. Numerous studies are ongoing regarding the standardization of SBRT in lung cancer treatment.